Clinical trial
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00003616 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00003616 |
|---|---|
| Title | Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma |
| Official title | Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Start date | Oct 22, 1998 |
| Primary completion | May 17, 2002 |
| Completion | Dec 20, 2005 |
| First posted | Feb 9, 2004 |
| Last update posted | Jun 27, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: